Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20140199 | 0.98 | HTR2C (0.45) | HTR2CHTR2AHTR2BDRD2DRD3 | |
| SCHEMBL16455042 | 0.90 | DRD2 (0.55) | HTR2ADRD2DRD3 | |
| SCHEMBL1513147 | 0.89 | HTR2C (0.55) | HTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL16445967 | 0.89 | DRD2 (0.54) | HTR2ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL4739383 | 0.88 | HTR2C (0.56) | HTR2C | |
| SCHEMBL20139888 | 0.83 | HTR2C (0.49) | HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL29580963 | 0.79 | ADRA1A (0.49) | ADRA1A | |
| SCHEMBL3167985 | 0.79 | ADRA1A (0.49) | ADRA1A | |
| SCHEMBL3823877 | 0.78 | HTR2C (0.41) | HTR2CHTR2AHTR2BDRD2DRD3 | |
| SCHEMBL28533805 | 0.77 | HTR2C (0.57) | HTR2CCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| CN-106573073-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2017-04-19 | — | — | CN | disclosed |
| US-20090270447-A1 | 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009120849-A1 | 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | WYETH (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270447-A1 | 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | CYP2U1, SEC22B, SEC63 | HTR2C 3387/4885HTR2A 4134/4885HTR2B 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.